• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Baxter Kidney Care is Now Vantive, A New Standalone Vital Organ Therapy Company

    2/3/25 7:00:00 AM ET
    $BAX
    $CG
    Medical/Dental Instruments
    Health Care
    Investment Managers
    Finance
    Get the next $BAX alert in real time by email

    Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and care teams with more flexible, collaborative and accessible care options

    With over 1 million daily interactions with patients across more than 100 countries, Vantive exists to extend lives and expand possibilities for patients everywhere

    DEERFIELD, Ill., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vantive, formerly the Baxter Kidney Care segment, today launched as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle (NASDAQ:CG) from Baxter International Inc. (NYSE:BAX). Vantive builds on a 70-year legacy as a leader in kidney care innovation to advance its mission of extending lives and expanding possibilities.

    As an independent company, Vantive is dedicated to elevating the standards of kidney and vital organ therapies with a vision to enable longer, fuller lives for patients everywhere. Approximately 4 million people worldwide receive dialysis treatment for chronic kidney disease.1 Access to this life-sustaining treatment varies across regions, and patients on dialysis often face physical and emotional burdens throughout the therapy process. Empowering patients and care teams, while helping to break down the barriers to starting and staying on therapy, is central to Vantive's strategy to advance vital organ therapies.

    "From patients beginning their dialysis journeys to clinicians fighting to save lives in the ICU, accessing the right therapy at the right time is critical. This is why our singular focus as Vantive is to empower more patients and care teams in these moments – with better options, greater control and expanded possibilities," said Chris Toth, CEO of Vantive. "We are beginning a new era of vital organ therapy innovation, and I am looking forward to working with our 23,000 global Vantive colleagues to make a difference for millions of patients and families around the world."

    The Vantive Difference

    Vantive delivers innovative products, digitally-enhanced solutions and advanced services to support dialysis at home and in the clinic, as well as critical care therapy to support the kidney and other vital organs in an intensive care unit (ICU) setting. Patients across more than 100 countries around the world interact with Vantive's people, solutions and services over 1 million times each day. This represents over 1 million opportunities to impact the patient experience every day.

    Through its fully integrated approach to innovation, Vantive seeks to help therapy fit more easily into providers' practices and patients' lives. Vantive's technologies and solutions are designed to elevate the therapy experience, expand efficiencies for care teams, and enhance outcomes for patients. For example, the use of Vantive's remote patient monitoring technology has been associated with lower incidence of all-cause mortality, fewer hospitalizations, reduced treatment drop-out, and greater treatment adherence for home dialysis.2

    "The launch of Vantive represents an important milestone in the continued evolution of kidney care and organ support," said Kieran Gallahue, Chair of the Vantive Board of Directors. "With a clear focus on enabling greater connection, visibility and insights throughout the care journey, Vantive is uniquely positioned to improve the therapy experience for patients and care teams. I am honored to support this dedicated team in advancing Vantive's important mission to extend lives and expand possibilities."

    "We are excited to partner with Vantive to expand the team's global impact and position the business for long-term success," said Robert Schmidt, Carlyle's Global Co-Head of Healthcare. "In this new chapter, Carlyle is committed to supporting Vantive's continued innovation to help enhance care accessibility, quality and outcomes for patients, as well as efficiency for clinicians."

    About Vantive

    Vantive is a vital organ therapy company on a mission to extend lives and expand possibilities for patients and care teams everywhere. For 70 years, our team has driven meaningful innovations in kidney care. Today, patients across more than 100 countries around the world interact with Vantive's people, solutions and services over 1 million times each day. As we build on our legacy, we are deepening our commitment to elevating the dialysis experience through digital solutions and advanced services, while looking beyond kidney care and investing in transforming vital organ therapies. Greater flexibility and efficiency in therapy administration for care teams, and longer, fuller lives for patients— that is what Vantive aspires to deliver. To learn more, visit www.vantive.com and follow us on LinkedIn, X, Facebook, Instagram and YouTube.

    Contact

    Vantive

    Katie Villany

    [email protected]

    ________________________

    1 Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96(5):1048-1050. doi:10.1016/j.kint.2019.07.012

    2 Paniagua R, Ramos A, Ávila M, et al. Remote monitoring of automated peritoneal dialysis reduces mortality, adverse events, and hospitalizations: a cluster randomized controlled trial. Nephrol Dial Transplant. Published online August 20, 2024. doi:10.1093/ndt/gfae188



    Primary Logo

    Get the next $BAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAX
    $CG

    CompanyDatePrice TargetRatingAnalyst
    The Carlyle Group Inc.
    $CG
    2/24/2026$67.00Outperform
    RBC Capital Mkts
    The Carlyle Group Inc.
    $CG
    12/11/2025$74.00Buy
    UBS
    Baxter International Inc.
    $BAX
    10/31/2025Buy → Hold
    Argus
    The Carlyle Group Inc.
    $CG
    10/3/2025$74.00Outperform
    BMO Capital Markets
    Baxter International Inc.
    $BAX
    8/4/2025$25.00Buy → Hold
    Stifel
    Baxter International Inc.
    $BAX
    8/1/2025$25.00Buy → Neutral
    Goldman
    The Carlyle Group Inc.
    $CG
    7/10/2025$65.00Neutral → Buy
    Citigroup
    The Carlyle Group Inc.
    $CG
    5/14/2025$56.00Hold → Buy
    TD Cowen
    More analyst ratings

    $BAX
    $CG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Carlyle Group with a new price target

    RBC Capital Mkts initiated coverage of Carlyle Group with a rating of Outperform and set a new price target of $67.00

    2/24/26 7:47:48 AM ET
    $CG
    Investment Managers
    Finance

    UBS resumed coverage on Carlyle Group with a new price target

    UBS resumed coverage of Carlyle Group with a rating of Buy and set a new price target of $74.00

    12/11/25 9:06:22 AM ET
    $CG
    Investment Managers
    Finance

    Baxter downgraded by Argus

    Argus downgraded Baxter from Buy to Hold

    10/31/25 8:47:22 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    $CG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rubenstein David M.

    4 - Carlyle Group Inc. (0001527166) (Issuer)

    3/20/26 5:34:13 PM ET
    $CG
    Investment Managers
    Finance

    Large owner Carlyle Group Inc. sold $1,070,339,440 worth of shares (26,105,840 units at $41.00) and disposed of 2,113,483 shares (SEC Form 4)

    4 - Carlyle Group Inc. (0001527166) (Reporting)

    3/12/26 4:30:20 PM ET
    $CG
    Investment Managers
    Finance

    SVP, CAO and Controller Zielinski Anita A covered exercise/tax liability with 1,932 shares, decreasing direct ownership by 4% to 46,281 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    3/10/26 4:08:56 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    $CG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baxter to Host Annual Meeting of Stockholders in Virtual Format

    Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2026 Annual Meeting) in a virtual format on Tuesday, May 5, 2026 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the 2026 Annual Meeting. Online access to the 2026 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2026 Annual Meeting in person. The virtual format provides a safe, convenient and cost-effective experience to all stockholders and employees, regardless of location. Anyone who would like to attend the virtual 2026 Annual Meeting is encouraged to access the meeting in advance of the designated star

    3/25/26 4:30:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Acentra Health Names New Senior Vice Presidents, Mohamed Karama and Nirav Dalal, to Drive Company Growth and Business Development

    MCLEAN, Va., March 25, 2026 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, announced today that Mohamed Karama has joined the company as Senior Vice President of Growth Acceleration and Performance, and Nirav Dalal has been promoted to Senior Vice President of Sales Leadership. These appointments advance Acentra Health's transformation initiatives and position the company for strategic growth. "As we continue transforming Acentra Health, we're investing in our growth engine," said Patty Obermaier, EVP, Chief Growth Offic

    3/25/26 9:33:00 AM ET
    $CG
    Investment Managers
    Finance

    Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot

    Largest Single Investment from a Corporate Foundation Aims to Strengthen Healthcare Resilience by Advancing Therapy Animal Visits in U.S. Healthcare SettingsBELLEVUE, Wash. and DEERFIELD, Ill., March 25, 2026 /PRNewswire/ -- Pet Partners, the nation's leading organization dedicated to improving human health and well-being through therapy animal interactions, and the Baxter Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced a new partnership to expand access to therapy animal programs in healthcare settings across the country. The initiative will begin as a two-year pilot program in key regions, including Northern California, Up

    3/25/26 9:00:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    $CG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by The Carlyle Group Inc.

    SCHEDULE 13G/A - Carlyle Group Inc. (0001527166) (Subject)

    3/26/26 4:44:46 PM ET
    $CG
    Investment Managers
    Finance

    SEC Form DEFA14A filed by Baxter International Inc.

    DEFA14A - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    3/23/26 8:52:56 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by Baxter International Inc.

    DEF 14A - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    3/23/26 8:51:59 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    $CG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    $CG
    Leadership Updates

    Live Leadership Updates

    View All

    Acentra Health Names New Senior Vice Presidents, Mohamed Karama and Nirav Dalal, to Drive Company Growth and Business Development

    MCLEAN, Va., March 25, 2026 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, announced today that Mohamed Karama has joined the company as Senior Vice President of Growth Acceleration and Performance, and Nirav Dalal has been promoted to Senior Vice President of Sales Leadership. These appointments advance Acentra Health's transformation initiatives and position the company for strategic growth. "As we continue transforming Acentra Health, we're investing in our growth engine," said Patty Obermaier, EVP, Chief Growth Offic

    3/25/26 9:33:00 AM ET
    $CG
    Investment Managers
    Finance

    Carlyle to Host 2026 Shareholder Update

    WASHINGTON and NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Global investment firm Carlyle (NASDAQ:CG) announced today that it will host a Shareholder Update on Thursday, February 26, 2026. The Shareholder Update will include a series of presentations by the company's senior leadership team and will review Carlyle's growth outlook and financial objectives. Presentations will begin at 8:30 a.m. EST, followed by a Q&A session. Presentation materials and a live webcast will be posted on the day of the event and can be accessed on the Events & Presentations section of ir.carlyle.com. For those unable to join the live webcast, a replay will be available on the website following the event. Any

    2/2/26 8:01:00 AM ET
    $CG
    Investment Managers
    Finance

    Acentra Health Appoints Balajee Sethuraman as Executive Vice President and Chief Business Services Officer

    MCLEAN, Va., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions company dedicated to accelerating better health outcomes for government and commercial clients and the populations they serve, today announced the appointment of Balajee Sethuraman as Executive Vice President and Chief Business Services Officer (CBSO), where he will lead the company's business services and delivery operations. This strategic addition to Acentra Health's executive leadership team supports its ongoing efforts to streamline and strengthen enterprise-wide delivery through a unified operating model. "Balajee is a transformative leader with exceptional experience scaling global team

    1/27/26 9:33:00 AM ET
    $CG
    Investment Managers
    Finance

    $BAX
    $CG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

    SC 13D/A - Carlyle Group Inc. (0001527166) (Subject)

    11/15/24 5:22:29 PM ET
    $CG
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

    SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)

    10/21/24 4:31:27 PM ET
    $CG
    Investment Managers
    Finance

    $BAX
    $CG
    Financials

    Live finance-specific insights

    View All

    Carlyle Presents Growth Outlook at 2026 Shareholder Update

    WASHINGTON and NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Global investment firm Carlyle (NASDAQ:CG) is announcing its growth outlook and financial objectives at the 2026 Shareholder Update, beginning today at 8:30 a.m. EST. The program will include presentations by senior leadership, followed by a Q&A session. Carlyle will announce three-year financial targets to be achieved by the end of 2028, including: FRE of $1.9+ billionInflows of $200+ billionDE per common share of $6.00+ Carlyle is also announcing that its Board of Directors has approved a new $2 billion share repurchase authorization. The authorization provides the firm with flexibility to repurchase shares as part of its disc

    2/26/26 7:01:00 AM ET
    $CG
    Investment Managers
    Finance

    Carlyle Secured Lending, Inc. Announces Financial Results For Fourth Quarter and Full Year Ended December 31, 2025, Declares First Quarter 2026 Dividend of $0.40 Per Common Share

    NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, "we," "us," "our," "CGBD" or the "Company") (NASDAQ:CGBD) today announced its financial results for its fourth quarter and full year ended December 31, 2025. Alex Chi, CGBD's Chief Executive Officer, said, "As CGBD's newly appointed CEO, I look forward to continuing to build on Carlyle's strong track record and world-class platform. Building off record origination volume in the fourth quarter and full year 2025, we continue to expand our origination apparatus and are focused on further harnessing the full power of the OneCarlyle platform. The depth of our underwriting se

    2/24/26 4:05:00 PM ET
    $CG
    $CGBD
    Investment Managers
    Finance
    Finance: Consumer Services

    Baxter Reports Fourth-Quarter 2025 Results

    Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis1,2 Fourth-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($2.01); adjusted diluted EPS from continuing operations of $0.44 Company advances ongoing board of directors refreshment Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. "While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise," said And

    2/12/26 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care